Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Pawlyn C, Bright MD, Buros AF, Stein CK, Walters Z, Aronson LI, Mirabella F, Jones JR, Kaiser MF, Walker BA, Jackson GH, Clarke PA, Bergsagel PL, Workman P, Chesi M, Morgan GJ, Davies FE.

Blood Cancer J. 2017 Mar 31;7(3):e549. doi: 10.1038/bcj.2017.27.

2.

Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor.

Lilly CL, Villa NY, Lemos de Matos A, Ali HM, Dhillon JS, Hofland T, Rahman MM, Chan W, Bogen B, Cogle C, McFadden G.

Mol Ther Oncolytics. 2016 Dec 14;4:31-40. doi: 10.1016/j.omto.2016.12.002. eCollection 2017 Mar 17.

3.

Stem cell transplantation for multiple myeloma: current and future status.

Giralt S, Bensinger W.

Leuk Suppl. 2013 May;2(Suppl 1):S10-4. doi: 10.1038/leusup.2013.3. Epub 2013 May 8. Review.

4.

Multiple Myeloma: Diagnosis and Treatment.

Rajkumar SV, Kumar S.

Mayo Clin Proc. 2016 Jan;91(1):101-19. doi: 10.1016/j.mayocp.2015.11.007. Review.

5.

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.

Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20.

6.

Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities.

Mactier CE, Islam MS.

Oncol Rev. 2012 Oct 4;6(2):e14. doi: 10.4081/oncol.2012.e14. eCollection 2012 Oct 2. Review.

7.

Curing myeloma at last: defining criteria and providing the evidence.

Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J.

Blood. 2014 Nov 13;124(20):3043-51. doi: 10.1182/blood-2014-07-552059. Epub 2014 Oct 7.

8.

Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II Study.

Byrne M, Salmasinia D, Leather H, Cogle CR, Davis A, Hsu JW, Wiggins L, Chang MN, An Q, Wingard JR, Moreb JS.

Clin Med Insights Oncol. 2014 Sep 3;8:101-5. doi: 10.4137/CMO.S16835. eCollection 2014.

9.

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers.

Mohty M, Harousseau JL.

Haematologica. 2014 Mar;99(3):408-16. doi: 10.3324/haematol.2013.096149. Review. No abstract available.

10.

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, June CH.

Clin Cancer Res. 2014 Mar 1;20(5):1355-65. doi: 10.1158/1078-0432.CCR-13-2817. Epub 2014 Feb 11.

11.

Total marrow irradiation as part of autologous stem cell transplantation for Asian patients with multiple myeloma.

Lin SC, Hsieh PY, Shueng PW, Tien HJ, Wang LY, Hsieh CH.

Biomed Res Int. 2013;2013:321762. doi: 10.1155/2013/321762. Epub 2013 Sep 8.

12.

Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation.

Kozelj M, Zver S, Zadnik V.

Radiol Oncol. 2013 May 21;47(2):161-5. doi: 10.2478/raon-2013-0019. Print 2013 Jun.

13.

Salvage second hematopoietic cell transplantation in myeloma.

Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P; Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research.

Biol Blood Marrow Transplant. 2013 May;19(5):760-6. doi: 10.1016/j.bbmt.2013.01.004. Epub 2013 Jan 5.

14.

Fifty years of melphalan use in hematopoietic stem cell transplantation.

Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2013 Mar;19(3):344-56. doi: 10.1016/j.bbmt.2012.08.011. Epub 2012 Aug 24. Review.

15.

Cure models as a useful statistical tool for analyzing survival.

Othus M, Barlogie B, Leblanc ML, Crowley JJ.

Clin Cancer Res. 2012 Jul 15;18(14):3731-6. doi: 10.1158/1078-0432.CCR-11-2859. Epub 2012 Jun 6.

16.

Therapy-related myeloid malignancies in myeloma.

Papanikolaou X, Barlogie B, Usmani SZ.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011047. doi: 10.4084/MJHID.2011.047. Epub 2011 Oct 24.

17.

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.

Qian J, Zheng Y, Zheng C, Wang L, Qin H, Hong S, Li H, Lu Y, He J, Yang J, Neelapu S, Kwak LW, Hou J, Yi Q.

Blood. 2012 Jan 5;119(1):161-9. doi: 10.1182/blood-2011-07-368472. Epub 2011 Nov 2.

18.

Evolving role of high dose stem cell therapy in multiple myeloma.

Gupta A, Kumar L.

Indian J Med Paediatr Oncol. 2011 Jan;32(1):17-24. doi: 10.4103/0971-5851.81885.

19.

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, Cross A, Philip S, Murphy H, Bhagat R, Zheng Z, Milliron T, Cotte J, Cannon A, Levine BL, Vonderheide RH, June CH.

Blood. 2011 Jan 20;117(3):788-97. doi: 10.1182/blood-2010-08-299396. Epub 2010 Oct 28.

20.

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences.

Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, Durie BG, Harousseau JL.

J Clin Oncol. 2010 Mar 1;28(7):1209-14. doi: 10.1200/JCO.2009.25.6081. Epub 2010 Jan 19. Erratum in: J Clin Oncol. 2010 Jul 20;28(21):3543.

Supplemental Content

Support Center